论文部分内容阅读
应用Ｂ超引导穿刺无水酒精注射法（ＰＥＩ）治疗复发肝癌１８例，并动态检测了外周血Ｔ淋巴细胞亚群，经随访对疗效进行分析。发现复发肝癌存在严重免疫抑制现象，ＣＤ４下降，ＣＤ８升高，ＣＤ４／ＣＤ８下降，但与初发肝癌组间无显著差别。经ＰＥＩ治疗后２周ＣＤ４、ＣＤ４／ＣＤ８升高，ＣＤ８下降，１１例肿瘤Ｂ超显示由低回声转为高环回声，３例混合回声，４例仍为低回声。随访１２例，共１４个肿瘤结节缩小。ｌ年生存率７８．８％，２年３２．９％。提示ＰＥＩ可有效治疗复发肝癌，减少肿瘤负荷，改善患者免疫状况。
A total of 18 patients with recurrent hepatocellular carcinoma were treated with B-guided percutaneous ethanol injection (PEI). Peripheral blood T lymphocyte subsets were detected dynamically. The efficacy was analyzed after follow-up. It was found that there was severe immunosuppression in recurrent HCC, CD4 decreased, CD8 increased, and CD4/CD8 decreased, but there was no significant difference from the primary HCC group. 2 weeks after PEI treatment, CD4, CD4/CD8 increased, CD8 decreased, 11 cases of B-mode ultrasound showed a transition from low echo to high echo, 3 cases mixed echo, and 4 cases remained hypoechoic. Follow-up of 12 patients, a total of 14 tumor nodules were reduced. l The annual survival rate is 78.8% and 32.9% for 2 years. It is suggested that PEI can effectively treat recurrent hepatocellular carcinoma, reduce tumor burden and improve patient immune status.